Table 1 Subject demographics and baseline characteristics (full analysis set population)
L50/H12.5 filter study | L100 filter study | |||
|---|---|---|---|---|
L50/H12.5 (n=144) | L100/H12.5 (n=134) | L100 (n=170) | L100/H12.5 (n=166) | |
Gender—n (%) | ||||
Male | 103 (71.5) | 102 (76.1) | 110 (64.7) | 129 (77.7) |
Female | 41 (28.5) | 32 (23.9) | 60 (35.3) | 37 (22.3) |
Age (years)—mean (s.d.) | 56.9 (10.7) | 57.8 (10.8) | 54.9 (9.5) | 55.7 (9.2) |
<65 years—n (%) | 111 (77.1) | 99 (73.9) | 144 (84.7) | 138 (83.1) |
⩾65 years—n (%) | 33 (22.9) | 35 (26.1) | 26 (15.3) | 28 (16.9) |
Body mass index (kg m−2)—mean (s.d.) | 26.1 (3.7) | 25.9 (3.7) | 26.3 (3.7) | 26.8 (4.8) |
Baseline SiDBP—n (%) | ||||
<100 mm Hg | 109 (75.7) | 113 (84.3) | 110 (64.7) | 115 (69.3) |
⩾100 mm Hg | 35 (24.3) | 21 (15.7) | 60 (35.3) | 51 (30.7) |
Type 2 diabetes—n (%) | 30 (20.8) | 25 (18.7) | 17 (10.0) | 22 (13.3) |
Dyslipidemia—n (%) | 57 (39.6) | 58 (43.3) | 57 (33.5) | 71 (42.8) |
Years of hypertension—mean (s.d.) | 6.7 (6.1) | 7.1 (6.8) | 5.8 (6.8) | 6.2 (6.6) |
No. of antihypertensive medications—n (%) | ||||
0 | 0 (0.0) | 0 (0.0) | 44 (25.9) | 33 (19.9) |
1 | 57 (39.6) | 45 (33.6) | 86 (50.6) | 83 (50.0) |
2 | 87 (60.4) | 89 (66.4) | 40 (23.5) | 50 (30.1) |
Renal function stage—n (%) | ||||
G1 (>90): normal or high eGFR value | 17 (11.8) | 21 (15.7) | 26 (15.3) | 29 (17.5) |
G2 (60–89): normal or mildly reduced function | 99 (68.8) | 91 (67.8) | 114 (67.1) | 113 (68.1) |
G3a (45–59): mildly to moderately reduced function | 20 (13.9) | 21 (15.7) | 28 (16.5) | 23 (13.9) |
G3b (30–44): moderately to severely reduced function | 8 (5.6) | 1 (0.7) | 2 (1.2) | 1 (0.6) |
